ClinicalTrials.gg
CompletedNCT03744676Updated Feb 27, 2025Results posted

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

A Phase 2 interventional study of lisocabtagene maraleucel in Lymphoma, Non-Hodgkin, Lymphoma and Lymphoma, B-Cell, sponsored by Juno Therapeutics, a Subsidiary of Celgene. Completed at 23 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-27.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Juno Therapeutics, a Subsidiary of Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb — none open to participants now, 1 under way, none of them phase 3. Lymphoma, Large B-Cell, Diffuse · Bristol-Myers Squibb.

Enrollment
10th of 19
104 · median 104
Started
2018
with 3 others
Phase 2
6 of 22
none open now
Registered
18th of 22
by date

Among the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb, this one is the 10th largest by enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2018, is one of 6 in phase 2, and was the 18th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

None of the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb is open now. The open studies under Lymphoma, Large B-Cell, Diffuse, anywhere →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 22 studies in Lymphoma, Large B-Cell, Diffuse by Bristol-Myers Squibb as a file.
02

Study summary

This is an open-label, multicenter, Phase 2 study to determine the safety, PK, and efficacy of lisocabtagene maraleucel (JCAR017) in subjects who have relapsed from, or are refractory to, two lines of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) in the outpatient setting. Subjects will receive treatment with JCAR017 and will be followed for up to 2 years.

Read the detailed description

This is an open-label, multicenter, Phase 2 study to assess the safety and antitumor activity in adult patients with relapsed or refractory B-cell non-Hodgkin Lymphoma when administered with lisocabtagene maraleucel (JCAR017) in the outpatient setting.

Upon the successful product generation of lisocabtagene maraleucel, subjects will enter the treatment phase of the study. Treatment will include lymphodepleting chemotherapy followed by lisocabtagene maraleucel administration. Subjects will then enter the post-treatment follow-up phase of the study and will be followed for approximately 24 months for safety, disease status, health-related quality of life (HRQoL), and survival. Long-term follow-up will continue under a separate long-term follow-up protocol, per health regulatory authority guidelines, currently up to 15 years after the last lisocabtagene maraleucel administration.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Neoplasms
  • Neoplasms by Histologic Type
  • Lymphoproliferative Disorders
  • Lymphatic Diseases
  • Immunoproliferative Disorders
  • Immune System Disorder

Keywords

  • Lisocabtagene maraleucel
  • liso-cel
  • JCAR017
  • relapse
  • refractory
  • B-Cell Non-Hodgkin Lymphoma
  • NHL
  • chimeric antigen receptor
  • CAR
  • CAR T cell
  • autologous T cell therapy
  • immunotherapy
  • cell therapy
  • B-cell malignancies
04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's enrollment of 104 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

First submitted before Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of consent
  • B-cell NHL of the following histologies: diffuse large B cell lymphoma (DLBCL) not otherwise specified; includes -confirmed transformed DLBCL from indolent histologies, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology, primary mediastinal B-cell lymphoma(PMBCL), and follicular lymphoma Grade 3B. Subjects must have been treated with an anthracycline and rituximab (or other CD20-targeted agent) and have relapsed or refractory disease after at least 2 systemic for DLBCL or after .
  • Positron-emission tomography-positive disease by Lugano Classification
  • performance status of 0 to 1
  • Adequate bone marrow, renal, hepatic, pulmonary, cardiac organ function
  • Adequate vascular access for leukapheresis procedure
  • Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy
  • Subjects must agree to use appropriate .

Exclusion criteria

Exclusion Criteria:

  • Subjects with central nervous system (CNS)-only involvement by (note: subjects with secondary CNS involvement are allowed on study)
  • History of prior hematopoietic stem cell transplant
  • Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis
  • History of another primary malignancy that has not been in remission for at least 2 years.The following are examples of exceptions from the 2-year limit: nonmelanoma skin cancer, definitively-treated stage 1 solid tumor with a low risk of recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on or a squamous intraepithelial lesion on a Papanicolau smear.
  • Active or infection at the time of screening
  • History of or active infection at the time of screening
  • Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate anti-infection treatment at the time of leukapheresis or lisocabtagene maraleucel administration
  • Presence of acute or chronic
  • History of cardiac conditions within the past 6 months
  • History or presence of clinically relevant CNS pathology such as epilepsy/seizure, paresis, aphasia, stroke, cerebral edema, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
  • Pregnant or nursing women
  • Subject does not meet protocol-specified for certain prior treatments
  • Prior CAR T-cell or other genetically modified T-cell therapy
  • Progressive vascular tumor invasion, thrombosis, or embolism
  • Venous thrombosis or embolism not managed on stable regimen of anticoagulation
  • Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Lisocabtagene maraleucel

    Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of lisocabtagene maraleucel. During lisocabtagene maraleucel production, subjects may receive low-dose chemotherapy for disease control. Upon successful generation of lisocabtagene maraleucel product, subjects will receive treatment which will include lymphodepleting chemotherapy followed by one dose of lisocabtagene maraleucel administered by intravenous (IV) injection.

    Biological: lisocabtagene maraleucel

Interventions

  • lisocabtagene maraleucel will be administered as single dose intravenous (IV) injection

    Also known as: JCAR017, liso-cel

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3

    Cytokine release syndrome is characterized by high fever, fatigue, nausea, headache, dyspnea, tachycardia, rigors, hypotension, hypoxia, myalgia/arthralgia, and anorexia. Incidence of Grade ≥ 3 CRS, based on the TEAE with MedDRA PT "Cytokine release syndrome," graded according to the grading scale adapted from Lee (Lee 2014).

    Time frame: From first dose to 90 days following first dose (up to approximately 90 days)

  2. Percentage of Participants With Neurotoxicity (NT) Adverse Events Grade ≥ 3

    NT events have also been reported and may include neurologic symptoms such as altered mental status, aphasia, altered level of consciousness, and seizures or seizure-like activity. Incidence of Grade ≥ 3 NT, defined as an Investigator-identified TEAE considered neurotoxicity related to JCAR017.

    Time frame: From first dose to 90 days following first dose (up to approximately 90 days)

  3. Percentage of Participants With Infection Adverse Events Grade ≥ 3

    Incidence of treatment-emergent Grade ≥ 3 infections, defined using MedDRA SOC.

    Time frame: From first dose to 90 days following first dose (up to approximately 90 days)

  4. Percentage of Participants With Grade ≥ 3 Prolonged Cytopenia at Day 29.

    Prolonged cytopenia is defined as the occurrence of Grade ≥ 3 cytopenia not resolved by the Day 29 visit, based on laboratory results of low hemoglobin, absolute neutrophil count decreased, and platelet count decreased. The frequency of subjects experiencing each individual laboratory abnormality and the total number with at least 1 abnormality will be summarized, as will recovery from prolonged cytopenia after Day 29.

    Time frame: At Day 29 after first treatment

Secondary outcomes

  1. Number of Participants With Adverse Events

    Time frame: From first dose to 90 days following first dose (up to approximately 90 days)

  2. Number of Participants With Clinically Significant Laboratory Abnormalities- Hematology

    Time frame: From first dose to up to 41 months

  3. Number of Participants With Clinically Significant Laboratory Abnormalities- Chemistry

    Time frame: From first dose to up to 41 months

  4. Number of Participants With Adverse Events Grade ≥ 3

    Time frame: From first dose to 90 days following first dose (up to approximately 90 days)

  5. Time to Onset and Time to Resolution of Grade ≥ 3 Cytokine Release Syndrome (CRS)

    Time frame: From first dose to up to approximately 41 months

  6. Time to Onset and Time to Resolution of Grade ≥ 3 Neurotoxicity (NT)

    Time frame: From first dose to up to approximately 41 months

  7. Number of Participants Administered Tocilizumab and Corticosteroid for Management of Cytokine Release Syndrome (CRS)

    Time frame: From first dose to up to approximately 41 months

  8. Number of Participants Administered Tocilizumab and Corticosteroid for Management of Neurotoxicity (NT)

    Time frame: From first dose to up to study completion (Approximately 57 Months and 24 days)

  9. Objective Response Rate (ORR)

    The Percentage of participants with a best overall response (BOR) of either CR or PR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as: 1. Score 1, 2, or 3a with or without residual mass 2. No evidence of FDG-avid disease in marrow Partial Response is defined as: 1. Score 4 or 5a with reduced uptake compared with baseline and residual masses of any size 2. Bone marrow with residual uptake higher than in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in marrow in the context of a nodal response, should consider further evaluation with MRI, biopsy, or interval scan.

    Time frame: From first dose to up to approximately 41 months

  10. Complete Response Rate (CRR)

    The Percentage of participants with a best overall response (BOR) with CR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as: 1. Score 1, 2, or 3a with or without residual mass 2. No evidence of FDG-avid disease in marrow

    Time frame: From first dose to up to approximately 41 months

  11. Duration of Response (DoR) and Duration of Complete Response (DoCR)

    Duration of response (DOR) is defined as the time from the first documentation of response (CR or PR) after JCAR017 infusion to disease progression or death from any cause, whichever occurs first. Duration of response (DOR) if BOR is CR is defined for subjects with a BOR of CR as the time from the first documentation of response (CR or PR) after JCAR017 infusion to earlier of disease progression or death from any cause.

    Time frame: From first dose to up to approximately 41 months

  12. Progression Free Survival (PFS)

    Progression-free survival is defined as the time from infusion of JCAR017 to progressive disease or death, whichever is earlier. If a subject does not have an event for the PFS analysis, the subject will be censored. Progressive Disease is defined as: 1. Score 4 or 5a with an increase in intensity of uptake from nadir 2. New FDG-avid foci consistent with lymphoma (may need biopsy or repeat scan if uncertain about etiology of foci). 3. Investigator assessed clinical progression

    Time frame: From first dose to up to study completion (Approximately 57 Months and 24 days)

  13. Overall Survival (OS)

    Overall survival is defined as the time from infusion of JCAR017 to the date of death. For assessment of OS, data from surviving participants will be censored at the last time that the participant is known to be alive. The OS analysis will include all available survival information from the long-term follow-up study if applicable.

    Time frame: From first dose to up to study completion (Approximately 57 Months and 24 days)

  14. Area Under the Blood Concentration-time Curve From Time to Zero to 28 Days After Dosing AUC (0-28)

    Time frame: 28days after first dose

  15. Maximum Observed Blood Concentration (Cmax)

    Time frame: 28days after first dose

  16. Time of Maximum Observed Blood Concentration (Tmax)

    Time frame: 28days after first dose

  17. Mean Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30

    The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A higher scale score represents a higher level of well-being and better ability of daily functioning. Thus, a high score for a functional scale represents a high/healthy level of functioning; a high score for the global health status/HRQoL represents a high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatic problem.

    Time frame: From Enrollment to end of follow up, approximately 26 months

  18. Mean Change From Baseline in EuroQol Instrument EQ-5D-5L.

    The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.530 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points.

    Time frame: Post Dose Month 24

  19. Number of Intensive Care Unit (ICU) Inpatient Days and Non-ICU Inpatient Days and Reasons for Hospitalization

    Length of initial ICU and non-ICU stay from liso-cel administration

    Time frame: From first hospitalization to the last. Approximately 31 days

  20. Number of Participants Who Received Transfusions

    Number of participants who received transfusions

    Time frame: From first dose to end of treatment period approximately 24 months

  21. Number of Participants Requiring Growth Factor Support.

    Growth factor support was defined as concomitant administration of FILGRASTIM, TBO FILGRASTIM, PEGFILGRASTIM, FILGRASTIM SNDZ, or FILGRASTIM AAFI.

    Time frame: From first dose to end of treatment period approximately 24 months

  22. Number of Participants Requiring Intravenous Immunoglobulin (IVIG) Support

    Number of participants requiring intravenous immunoglobulin (IVIG) support

    Time frame: From first dose to end of treatment period approximately 24 months

08

Results

Posted Dec 6, 2023

Participant flow

Pre-Treatment Phase
Participant flow — Pre-Treatment Phase
MilestoneLisocabtagene Maraleucel (JCAR017)
Started104
Completed84
Not completed20
Withdrew: Disease related complications2
Withdrew: No longer meets study criteria4
Withdrew: Death7
Withdrew: Other reasons7
Treatment Phase
Participant flow — Treatment Phase
MilestoneLisocabtagene Maraleucel (JCAR017)
Started82
Participants who received ldc and non conforming product1
Completed35
Not completed47
Withdrew: Participant withdrew consent8
Withdrew: Death33
Withdrew: Other reasons6

Outcome measures

PrimaryPercentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3

Cytokine release syndrome is characterized by high fever, fatigue, nausea, headache, dyspnea, tachycardia, rigors, hypotension, hypoxia, myalgia/arthralgia, and anorexia. Incidence of Grade ≥ 3 CRS, based on the TEAE with MedDRA PT "Cytokine release syndrome," graded according to the grading scale adapted from Lee (Lee 2014).

Time frame:
From first dose to 90 days following first dose (up to approximately 90 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 3
Percentage of participantsLisocabtagene Maraleucel (JCAR017)
Percentage of Participants With Cytokine Release Syndrome (CRS) Adverse Events Grade ≥ 30.0 (0.0 to 4.4)
PrimaryPercentage of Participants With Neurotoxicity (NT) Adverse Events Grade ≥ 3

NT events have also been reported and may include neurologic symptoms such as altered mental status, aphasia, altered level of consciousness, and seizures or seizure-like activity. Incidence of Grade ≥ 3 NT, defined as an Investigator-identified TEAE considered neurotoxicity related to JCAR017.

Time frame:
From first dose to 90 days following first dose (up to approximately 90 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Neurotoxicity (NT) Adverse Events Grade ≥ 3
Percentage of participantsLisocabtagene Maraleucel (JCAR017)
Percentage of Participants With Neurotoxicity (NT) Adverse Events Grade ≥ 39.8 (4.3 to 18.3)
PrimaryPercentage of Participants With Infection Adverse Events Grade ≥ 3

Incidence of treatment-emergent Grade ≥ 3 infections, defined using MedDRA SOC.

Time frame:
From first dose to 90 days following first dose (up to approximately 90 days)
Reported as:
Number · Percentage of participants
Percentage of Participants With Infection Adverse Events Grade ≥ 3
Percentage of participantsLisocabtagene Maraleucel (JCAR017)
Percentage of Participants With Infection Adverse Events Grade ≥ 311.0 (5.1 to 19.8)
PrimaryPercentage of Participants With Grade ≥ 3 Prolonged Cytopenia at Day 29.

Prolonged cytopenia is defined as the occurrence of Grade ≥ 3 cytopenia not resolved by the Day 29 visit, based on laboratory results of low hemoglobin, absolute neutrophil count decreased, and platelet count decreased. The frequency of subjects experiencing each individual laboratory abnormality and the total number with at least 1 abnormality will be summarized, as will recovery from prolonged cytopenia after Day 29.

Time frame:
At Day 29 after first treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade ≥ 3 Prolonged Cytopenia at Day 29.
Percentage of participantsLisocabtagene Maraleucel (JCAR017)
Percentage of Participants With Grade ≥ 3 Prolonged Cytopenia at Day 29.32.9 (22.9 to 44.2)
SecondaryNumber of Participants With Adverse Events
Time frame:
From first dose to 90 days following first dose (up to approximately 90 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsLisocabtagene Maraleucel (JCAR017)
Number of Participants With Adverse Events82
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities- Hematology
Time frame:
From first dose to up to 41 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities- Hematology
ParticipantsLisocabtagene Maraleucel (JCAR017)
Number of Participants With Clinically Significant Laboratory Abnormalities- Hematology0
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities- Chemistry
Time frame:
From first dose to up to 41 months
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities- Chemistry
ParticipantsLisocabtagene Maraleucel (JCAR017)
Number of Participants With Clinically Significant Laboratory Abnormalities- Chemistry0
SecondaryNumber of Participants With Adverse Events Grade ≥ 3
Time frame:
From first dose to 90 days following first dose (up to approximately 90 days)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events Grade ≥ 3
ParticipantsLisocabtagene Maraleucel (JCAR017)
Number of Participants With Adverse Events Grade ≥ 361
SecondaryTime to Onset and Time to Resolution of Grade ≥ 3 Cytokine Release Syndrome (CRS)
Time frame:
From first dose to up to approximately 41 months
Reported as:
Median · Days
Time to Onset and Time to Resolution of Grade ≥ 3 Cytokine Release Syndrome (CRS)
DaysLisocabtagene Maraleucel (JCAR017)
Time to Onset0 (0 to 0)
Time to Resolution0 (0 to 0)
SecondaryTime to Onset and Time to Resolution of Grade ≥ 3 Neurotoxicity (NT)
Time frame:
From first dose to up to approximately 41 months
Reported as:
Median · Days
Time to Onset and Time to Resolution of Grade ≥ 3 Neurotoxicity (NT)
DaysLisocabtagene Maraleucel (JCAR017)
Time to Onset9.5 (3 to 33)
Time to Resolution16.5 (5 to 47)
SecondaryNumber of Participants Administered Tocilizumab and Corticosteroid for Management of Cytokine Release Syndrome (CRS)
Time frame:
From first dose to up to approximately 41 months
Reported as:
Count of participants · Participants
Number of Participants Administered Tocilizumab and Corticosteroid for Management of Cytokine Release Syndrome (CRS)
ParticipantsLisocabtagene Maraleucel (JCAR017)
Tocilizumab Only7
Corticosteroid Only2
Both Tocilizumab and Corticosteroid7
SecondaryNumber of Participants Administered Tocilizumab and Corticosteroid for Management of Neurotoxicity (NT)
Time frame:
From first dose to up to study completion (Approximately 57 Months and 24 days)
Reported as:
Count of participants · Participants
Number of Participants Administered Tocilizumab and Corticosteroid for Management of Neurotoxicity (NT)
ParticipantsLisocabtagene Maraleucel (JCAR017)
Tocilizumab Only0
Corticosteroid Only12
Both Tocilizumab and Corticosteroid1
SecondaryObjective Response Rate (ORR)

The Percentage of participants with a best overall response (BOR) of either CR or PR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as: 1. Score 1, 2, or 3a with or without residual mass 2. No evidence of FDG-avid disease in marrow Partial Response is defined as: 1. Score 4 or 5a with reduced uptake compared with baseline and residual masses of any size 2. Bone marrow with residual uptake higher than in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in marrow in the context of a nodal response, should consider further evaluation with MRI, biopsy, or interval scan.

Time frame:
From first dose to up to approximately 41 months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR)
Percentage of ParticipantsLisocabtagene Maraleucel (JCAR017)
Objective Response Rate (ORR)80.5 (70.3 to 88.4)
SecondaryComplete Response Rate (CRR)

The Percentage of participants with a best overall response (BOR) with CR based on the Lugano 2014 criteria. Disease response will be determined according to the "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification" Complete response is defined as: 1. Score 1, 2, or 3a with or without residual mass 2. No evidence of FDG-avid disease in marrow

Time frame:
From first dose to up to approximately 41 months
Reported as:
Number · Percentage of Participants
Complete Response Rate (CRR)
Percentage of ParticipantsLisocabtagene Maraleucel (JCAR017)
Complete Response Rate (CRR)53.7 (42.3 to 64.7)
SecondaryDuration of Response (DoR) and Duration of Complete Response (DoCR)

Duration of response (DOR) is defined as the time from the first documentation of response (CR or PR) after JCAR017 infusion to disease progression or death from any cause, whichever occurs first. Duration of response (DOR) if BOR is CR is defined for subjects with a BOR of CR as the time from the first documentation of response (CR or PR) after JCAR017 infusion to earlier of disease progression or death from any cause.

Time frame:
From first dose to up to approximately 41 months
Reported as:
Median · Months
Duration of Response (DoR) and Duration of Complete Response (DoCR)
MonthsLisocabtagene Maraleucel (JCAR017)
DoR14.75 (5.03 to NA)
DoCRNA (16.59 to NA)
SecondaryProgression Free Survival (PFS)

Progression-free survival is defined as the time from infusion of JCAR017 to progressive disease or death, whichever is earlier. If a subject does not have an event for the PFS analysis, the subject will be censored. Progressive Disease is defined as: 1. Score 4 or 5a with an increase in intensity of uptake from nadir 2. New FDG-avid foci consistent with lymphoma (may need biopsy or repeat scan if uncertain about etiology of foci). 3. Investigator assessed clinical progression

Time frame:
From first dose to up to study completion (Approximately 57 Months and 24 days)
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsLisocabtagene Maraleucel (JCAR017)
Progression Free Survival (PFS)5.86 (0.7 to 26.7)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from infusion of JCAR017 to the date of death. For assessment of OS, data from surviving participants will be censored at the last time that the participant is known to be alive. The OS analysis will include all available survival information from the long-term follow-up study if applicable.

Time frame:
From first dose to up to study completion (Approximately 57 Months and 24 days)
Reported as:
Median · Months
Overall Survival (OS)
MonthsLisocabtagene Maraleucel (JCAR017)
Overall Survival (OS)21.88 (1.0 to 50.1)
SecondaryArea Under the Blood Concentration-time Curve From Time to Zero to 28 Days After Dosing AUC (0-28)
Time frame:
28days after first dose
Reported as:
Geometric mean · day*copies/μg
Area Under the Blood Concentration-time Curve From Time to Zero to 28 Days After Dosing AUC (0-28)
day*copies/μgLisocabtagene Maraleucel (JCAR017)
Area Under the Blood Concentration-time Curve From Time to Zero to 28 Days After Dosing AUC (0-28)219760.3 ± 216.1
SecondaryMaximum Observed Blood Concentration (Cmax)
Time frame:
28days after first dose
Reported as:
Geometric mean · copies/μg
Maximum Observed Blood Concentration (Cmax)
copies/μgLisocabtagene Maraleucel (JCAR017)
Maximum Observed Blood Concentration (Cmax)24077.8 ± 230.7
SecondaryTime of Maximum Observed Blood Concentration (Tmax)
Time frame:
28days after first dose
Reported as:
Median · days
Time of Maximum Observed Blood Concentration (Tmax)
daysLisocabtagene Maraleucel (JCAR017)
Time of Maximum Observed Blood Concentration (Tmax)10.0 (7 to 28)
SecondaryMean Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30

The EORTC QLQ-C30 is a 30-item scale composed of both multi-item scales and single-item measures. All of the scales and single-item measures range in score from 0 to 100. A higher scale score represents a higher level of well-being and better ability of daily functioning. Thus, a high score for a functional scale represents a high/healthy level of functioning; a high score for the global health status/HRQoL represents a high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatic problem.

Time frame:
From Enrollment to end of follow up, approximately 26 months
Reported as:
Mean · Scores on a Scale
Mean Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30
Scores on a ScaleLisocabtagene Maraleucel (JCAR017)
Apptetie Loss-22.7 ± 23.87
Cognitive Functioning1.5 ± 18.48
Constipation-7.6 ± 27.08
Diarrhea-3.0 ± 27.04
Dyspnea6.1 ± 13.16
Emotional Functioning2.7 ± 20.31
Fatigue-14.6 ± 21.24
Financial Difficulties-9.1 ± 25.58
Global Health Stuats/QoL15.2 ± 21.61
Insomnia-10.6 ± 27.96
Nausea and Vomiting-9.8 ± 17.56
Pain-13.6 ± 26.55
Physical Functioning2.4 ± 16.14
Role Functioning12.9 ± 23.53
Social Functioning17.4 ± 24.92
SecondaryMean Change From Baseline in EuroQol Instrument EQ-5D-5L.

The European Quality of Life 5D-5L Scale (EQ-5D-5L) assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Responses are coded so that a '1' indicates no problem, and '5' indicates the most serious problem. The responses for the 5 dimensions are combined in a 5-digit number. The EQ-5D-5L health utility index (HUI) is assessed using the Crosswalk algorithm for France based on the individual responses to the 5 EQ-5D-5L domains ranging from -0.530 to 1.000. The smallest change considered clinically meaningful, is defined as a score difference of 0.08 points.

Time frame:
Post Dose Month 24
Reported as:
Mean · Score on a Scale
Mean Change From Baseline in EuroQol Instrument EQ-5D-5L.
Score on a ScaleLisocabtagene Maraleucel (JCAR017)
Mean Change From Baseline in EuroQol Instrument EQ-5D-5L.0.0 ± 0.13
SecondaryNumber of Intensive Care Unit (ICU) Inpatient Days and Non-ICU Inpatient Days and Reasons for Hospitalization

Length of initial ICU and non-ICU stay from liso-cel administration

Time frame:
From first hospitalization to the last. Approximately 31 days
Reported as:
Median · days
Number of Intensive Care Unit (ICU) Inpatient Days and Non-ICU Inpatient Days and Reasons for Hospitalization
daysLisocabtagene Maraleucel (JCAR017)
Initial ICU Stay5.5 (4 to 7)
Initial Non-ICU Stay15.0 (0 to 31)
SecondaryNumber of Participants Who Received Transfusions

Number of participants who received transfusions

Time frame:
From first dose to end of treatment period approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Who Received Transfusions
ParticipantsLisocabtagene Maraleucel (JCAR017)
Number of Participants Who Received Transfusions43
SecondaryNumber of Participants Requiring Growth Factor Support.

Growth factor support was defined as concomitant administration of FILGRASTIM, TBO FILGRASTIM, PEGFILGRASTIM, FILGRASTIM SNDZ, or FILGRASTIM AAFI.

Time frame:
From first dose to end of treatment period approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Requiring Growth Factor Support.
ParticipantsLisocabtagene Maraleucel (JCAR017)
Number of Participants Requiring Growth Factor Support.35
SecondaryNumber of Participants Requiring Intravenous Immunoglobulin (IVIG) Support

Number of participants requiring intravenous immunoglobulin (IVIG) support

Time frame:
From first dose to end of treatment period approximately 24 months
Reported as:
Count of participants · Participants
Number of Participants Requiring Intravenous Immunoglobulin (IVIG) Support
ParticipantsLisocabtagene Maraleucel (JCAR017)
Number of Participants Requiring Intravenous Immunoglobulin (IVIG) Support12

Adverse events

Collected over Participants were assessed for all-cause mortality from their first dose until study completion (up to approximately 57 months and 24 days). SAEs and Other AEs were assessed from first dose to 90 days following first dose (up to approximately 90 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisocabtagene Maraleucel (JCAR017)48/82 (58.5%)48/82 (58.5%)82/82 (100%)
Most frequent serious events
Showing 10 of 56
Most frequent serious events
EventLisocabtagene Maraleucel (JCAR017)
Cytokine release syndromeImmune system disorders24/82
Febrile neutropeniaBlood and lymphatic system disorders5/82
SepsisInfections and infestations5/82
PyrexiaGeneral disorders4/82
Cognitive disorderNervous system disorders4/82
EncephalopathyNervous system disorders4/82
TremorNervous system disorders4/82
HeadacheNervous system disorders3/82
NeutropeniaBlood and lymphatic system disorders2/82
Supraventricular tachycardiaCardiac disorders2/82
Most frequent other events
Showing 10 of 38
Most frequent other events
EventLisocabtagene Maraleucel (JCAR017)
NeutropeniaBlood and lymphatic system disorders55/82
LeukopeniaBlood and lymphatic system disorders36/82
ThrombocytopeniaBlood and lymphatic system disorders29/82
AnaemiaBlood and lymphatic system disorders28/82
FatigueGeneral disorders25/82
NauseaGastrointestinal disorders21/82
HeadacheNervous system disorders20/82
ConstipationGastrointestinal disorders19/82
DiarrhoeaGastrointestinal disorders19/82
Decreased appetiteMetabolism and nutrition disorders19/82

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Lisocabtagene Maraleucel (JCAR017)
Mean64.9 ± 11.61
Sex: Female, Male
Sex: Female, Male(Participants)Lisocabtagene Maraleucel (JCAR017)
Female38
Male66
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lisocabtagene Maraleucel (JCAR017)
Hispanic or Latino19
Not Hispanic or Latino77
Unknown or Not Reported8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lisocabtagene Maraleucel (JCAR017)
White88
Other7
Unknown9
09

Study locations

23 sites
  • Local Institution - 0057
    Los Angeles, California 90048, United States
  • Local Institution - 0060
    Denver, Colorado 80218, United States
  • Local Institution - 0089
    Miami, Florida 33176, United States
  • Local Institution - 0081
    Orlando, Florida 32804, United States
  • Local Institution - 0065
    Indianapolis, Indiana 46237, United States
  • Local Institution - 0069
    Wichita, Kansas 67124, United States
  • Local Institution - 0064
    Louisville, Kentucky 40207, United States
  • Local Institution - 0101
    Southfield, Michigan 48075, United States
  • Local Institution - 0052
    East Brunswick, New Jersey 08816, United States
  • Local Institution - 0066
    Morristown, New Jersey 07962, United States
  • Local Institution - 0041
    Albany, New York 12208, United States
  • Local Institution - 0039
    Cincinnati, Ohio 45236, United States
  • Local Institution - 0098
    Eugene, Oregon 97401, United States
  • Local Institution - 0051
    Portland, Oregon 97213, United States
  • Lancaster General Hospital
    Lancaster, Pennsylvania 17604, United States
  • Local Institution - 0037
    Greenville, South Carolina 29615, United States
  • Local Institution - 0063
    Nashville, Tennessee 37203, United States
  • Local Institution - 0097
    Dallas, Texas 75230, United States
  • Local Institution - 0061
    San Antonio, Texas 78229, United States
  • Baylor Scott and White Health
    Temple, Texas 76508, United States
  • Local Institution - 0096
    Tyler, Texas 75702, United States
  • Local Institution - 0074
    Salt Lake City, Utah 84143, United States
  • Local Institution - 0036
    Norfolk, Virginia 23502, United States
10

References and documents

Publications

  • Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Sep 2023, 57 months.

Results were first posted in Dec 2023, 2 months after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 57. This study's 57 months is above that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2018
First posted
Nov 16, 2018
StartActual
Nov 29, 2018
Primary completionActual
Sep 22, 2023
CompletionActual
Sep 22, 2023
Results first posted
Dec 6, 2023
Last update
Feb 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03744676
Responsible party
Sponsor
First posted
Nov 16, 2018
Start date
Nov 29, 2018
Primary completion
Sep 22, 2023
Completion
Sep 22, 2023
Results posted
Dec 6, 2023
Last update
Feb 27, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisocabtagene maraleucel

Start the discussion